Skip to main content

CORRECTION article

Front. Immunol., 24 August 2023
Sec. Viral Immunology
Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1275925
This article is part of the Research Topic COVID and Emerging Infectious Diseases View all 47 articles

Corrigendum: Neuro-PASC is characterized by enhanced CD4+ and diminished CD8+ T cell responses to SARSCoV-2 Nucleocapsid protein

This article is a correction to:

  1. Neuro-PASC is characterized by enhanced CD4+ and diminished CD8+ T cell responses to SARS-CoV-2 Nucleocapsid protein

    1. Read original article
Lavanya Visvabharathy*Lavanya Visvabharathy1*Barbara A. HansonBarbara A. Hanson1Zachary S. OrbanZachary S. Orban1Patrick H. LimPatrick H. Lim1Nicole M. PalacioNicole M. Palacio2Millenia JimenezMillenia Jimenez1Jeffrey R. ClarkJeffrey R. Clark1Edith L. GrahamEdith L. Graham1Eric M. LiottaEric M. Liotta1George TachasGeorge Tachas3Pablo Penaloza-MacMasterPablo Penaloza-MacMaster2Igor J. Koralnik*Igor J. Koralnik1*
  • 1Ken and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States
  • 2Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States
  • 3Drug Discovery & Patents, Antisense Therapeutics Ltd., Melbourne, VIC, Australia

A corrigemdum on
Neuro-PASC is characterized by enhanced CD4+ and diminished CD8+ T cell responses to SARS-CoV-2 Nucleocapsid protein

by Visvabharathy L, Hanson BA, Orban ZS, Lim PH, Palacio NM, Jimenez M, Clark JR, Graham EL, Liotta EM, Tachas G, Penaloza-MacMaster P and Koralnik IJ (2023) 14:1155770. doi: 10.3389/fimmu.2023.1155770

In the published article, there was an error in Figure 4 as published. The figure legend did not match the figure panels. The corrected Figure 4 and its caption appear below.

FIGURE 4
www.frontiersin.org

Figure 4 Elevated Nucleocapsid-specific CD4+ T cell and attenuated CD8+ memory T cell activation in Neuro-PASC patients (A) CD8+ TEM from NP patients show decreased activation after stimulation with N peptides. (B) Higher percentages of CD8+ TEMRA cells are found in NP patients compared to control groups. (C) CD8+ TEMRA cells from NP patients are less activated by N peptides compared with CC subjects. (D) CD8+ TEM from NP patients have enhanced IL-6 production after N antigen stimulation compared to CC subjects on a per-cell basis (mean fluorescence intensity; MFI). (E) Increased soluble IL-6 and IL6Rβ in NP patient plasma compared with CC subjects. Data combined from 5 independent experiments with the indicated n values. *p<0.05, **p<0.01, ****p<0.0001 using two-tailed Student’s t test with Welch’s correction. “ns”, not significant.

In the published article, there was an error in Figure S2 as published. There was a grammatical error in the figure legend. The corrected Figure S2 and its caption appear in the Supplementary Material.

In the published article, there was an error in Figure S4 as published. There was a mistake in the figure title and the caption. The corrected Figure S4 and its caption appear in the Supplementary Material.

In the published article, there was an error in Figure S6 as published. There was a grammatical error in the caption. The corrected Figure S6 and its caption appear in the Supplementary Material.

In the published article, there was an error in Figure S8 as published. There was an extra word “classical” in the figure caption. The corrected Figure S8 and its caption appear in the Supplementary Material.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: COVID-19 immunity, T cell memory, neuro-PASC, IL-6, immunoregulation, proteomics, long COVID

Citation: Visvabharathy L, Hanson BA, Orban ZS, Lim PH, Palacio NM, Jimenez M, Clark JR, Graham EL, Liotta EM, Tachas G, Penaloza-MacMaster P and Koralnik IJ (2023) Corrigendum: Neuro-PASC is characterized by enhanced CD4+ and diminished CD8+ T cell responses to SARSCoV-2 Nucleocapsid protein. Front. Immunol. 14:1275925. doi: 10.3389/fimmu.2023.1275925

Received: 10 August 2023; Accepted: 14 August 2023;
Published: 24 August 2023.

Edited and Reviewed by:

Ulises Gomez-Pinedo, Health Research Institute of Hospital Clínico San Carlos, Spain

Copyright © 2023 Visvabharathy, Hanson, Orban, Lim, Palacio, Jimenez, Clark, Graham, Liotta, Tachas, Penaloza-MacMaster and Koralnik. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Lavanya Visvabharathy, lavanya.visvabharathy@northwestern.edu; Igor J. Koralnik, igor.koralnik@northwestern.edu

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.